203 related articles for article (PubMed ID: 31448653)
1. Post-translational modifications of proteins in antiphospholipid antibody syndrome.
Buttari B; Profumo E; Capozzi A; Saso L; Sorice M; Riganò R
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):511-525. PubMed ID: 31448653
[TBL] [Abstract][Full Text] [Related]
2. β2-Glycoprotein I-Reactive T Cells in Autoimmune Disease.
Rauch J; Salem D; Subang R; Kuwana M; Levine JS
Front Immunol; 2018; 9():2836. PubMed ID: 30619248
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I.
Passam FH; Giannakopoulos B; Mirarabshahi P; Krilis SA
J Thromb Haemost; 2011 Jul; 9 Suppl 1():275-82. PubMed ID: 21781264
[TBL] [Abstract][Full Text] [Related]
4. β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome.
Tanimura K; Jin H; Suenaga T; Morikami S; Arase N; Kishida K; Hirayasu K; Kohyama M; Ebina Y; Yasuda S; Horita T; Takasugi K; Ohmura K; Yamamoto K; Katayama I; Sasazuki T; Lanier LL; Atsumi T; Yamada H; Arase H
Blood; 2015 Apr; 125(18):2835-44. PubMed ID: 25733579
[TBL] [Abstract][Full Text] [Related]
5. IgG autoantibodies against beta2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome.
Lopez D; Kobayashi K; Merrill JT; Matsuura E; Lopez LR
Clin Dev Immunol; 2003; 10(2-4):203-11. PubMed ID: 14768953
[TBL] [Abstract][Full Text] [Related]
6. Autoreactive CD4(+) T-cell clones to beta2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site.
Arai T; Yoshida K; Kaburaki J; Inoko H; Ikeda Y; Kawakami Y; Kuwana M
Blood; 2001 Sep; 98(6):1889-96. PubMed ID: 11535526
[TBL] [Abstract][Full Text] [Related]
7. Beta2-glycoprotein I: antiphospholipid syndrome and T-cell reactivity.
Kuwana M
Thromb Res; 2004; 114(5-6):347-55. PubMed ID: 15507264
[TBL] [Abstract][Full Text] [Related]
8. OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement.
Lopez LR; Simpson DF; Hurley BL; Matsuura E
Ann N Y Acad Sci; 2005 Jun; 1051():313-22. PubMed ID: 16126973
[TBL] [Abstract][Full Text] [Related]
9. {beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome.
Sikara MP; Routsias JG; Samiotaki M; Panayotou G; Moutsopoulos HM; Vlachoyiannopoulos PG
Blood; 2010 Jan; 115(3):713-23. PubMed ID: 19805618
[TBL] [Abstract][Full Text] [Related]
10. Overlapping humoral autoimmunity links rheumatic fever and the antiphospholipid syndrome.
Blank M; Krause I; Magrini L; Spina G; Kalil J; Jacobsen S; Thiesen HJ; Cunningham MW; Guilherme L; Shoenfeld Y
Rheumatology (Oxford); 2006 Jul; 45(7):833-41. PubMed ID: 16705050
[TBL] [Abstract][Full Text] [Related]
11. [Anti-beta2 glycoprotein I-beta2 glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases.
Biasiolo A; Rampazzo P; Brocco T; Barbero F; Rosato A; Pengo V
Lupus; 1999; 8(2):121-6. PubMed ID: 10192506
[TBL] [Abstract][Full Text] [Related]
12. Glycopeptide profiling of beta-2-glycoprotein I by mass spectrometry reveals attenuated sialylation in patients with antiphospholipid syndrome.
Kondo A; Miyamoto T; Yonekawa O; Giessing AM; Østerlund EC; Jensen ON
J Proteomics; 2009 Nov; 73(1):123-33. PubMed ID: 19706343
[TBL] [Abstract][Full Text] [Related]
13. Atherogenic oxidized low-density lipoprotein/beta2-glycoprotein I (oxLDL/beta2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome.
Matsuura E; Kobayashi K; Hurley BL; Lopez LR
Lupus; 2006; 15(7):478-83. PubMed ID: 16898186
[TBL] [Abstract][Full Text] [Related]
14. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on β2GPI-specific T cell response.
Conti F; Spinelli FR; Alessandri C; Pacelli M; Ceccarelli F; Marocchi E; Montali A; Capozzi A; Buttari B; Profumo E; Sorice M; Arca M; Valesini G; Riganò R
Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):661-8. PubMed ID: 24436371
[TBL] [Abstract][Full Text] [Related]
15. Antiphospholipid syndrome: 30 years and our contribution.
Koike T
Int J Rheum Dis; 2015 Feb; 18(2):233-41. PubMed ID: 25524556
[TBL] [Abstract][Full Text] [Related]
16. The Role of TLR4 on B Cell Activation and Anti-
Cheng S; Wang H; Zhou H
J Immunol Res; 2016; 2016():1719720. PubMed ID: 27868072
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms of "Antiphospholipid Antibodies" and Their Paradoxical Role in the Pathogenesis of "Seronegative APS".
Misasi R; Longo A; Recalchi S; Caissutti D; Riitano G; Manganelli V; Garofalo T; Sorice M; Capozzi A
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33182499
[TBL] [Abstract][Full Text] [Related]
18. Beta 2 glycoprotein I and neutrophil extracellular traps: Potential bridge between innate and adaptive immunity in anti-phospholipid syndrome.
Grossi C; Capitani N; Benagiano M; Baldari CT; Della Bella C; Macor P; Tedesco F; Borghi MO; Maugeri N; D'Elios MM; Meroni PL
Front Immunol; 2022; 13():1076167. PubMed ID: 36700193
[TBL] [Abstract][Full Text] [Related]
19. Atherogenic antiphospholipid antibodies in antiphospholipid syndrome.
Kobayashi K; Lopez LR; Matsuura E
Ann N Y Acad Sci; 2007 Jun; 1108():489-96. PubMed ID: 17894014
[TBL] [Abstract][Full Text] [Related]
20. Beta2-glycoprotein I: target antigen for 'antiphospholipid' antibodies. Immunological and molecular aspects.
Sheng Y; Kandiah DA; Krilis SA
Lupus; 1998; 7 Suppl 2():S5-9. PubMed ID: 9814663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
